Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
verinurad
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Verinurad is a novel, orally active, small molecule drug that acts as a potent and selective inhibitor of the urate transporter 1 (URAT1). It is in clinical development primarily for the treatment of gout and asymptomatic hyperuricemia. By inhibiting URAT1, verinurad reduces the reabsorption of uric acid in the kidneys, thereby increasing its excretion and lowering serum urate levels. Verinurad has also been investigated for potential use in heart failure. The drug is structurally distinct from other URAT1 inhibitors such as lesinurad but shares a similar mechanism of action. AstraZeneca is developing verinurad[3][5][6][7].
- Other names
- verinurad
02
Targets
URAT1 (Uric Acid Transporter 1)
Beyond the preview
Go deeper on verinurad.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on verinurad.